Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Checkpoint Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CKPT
Nasdaq
8731
https://checkpointtx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Checkpoint Therapeutics Inc
Checkpoint Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 24th, 2024 1:11 pm
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Mar 22nd, 2024 12:30 pm
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
- Mar 18th, 2024 12:00 pm
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
- Jan 29th, 2024 1:00 pm
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
- Jan 11th, 2024 1:15 pm
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook
- Dec 19th, 2023 12:36 pm
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
- Dec 18th, 2023 12:31 pm
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
- Dec 18th, 2023 12:00 pm
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
- Dec 11th, 2023 5:26 pm
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
- Dec 5th, 2023 1:30 pm
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Nov 13th, 2023 10:00 pm
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
- Oct 18th, 2023 12:30 pm
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
- Oct 2nd, 2023 4:53 pm
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
- Sep 21st, 2023 12:30 pm
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 12:30 pm
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 14th, 2023 8:15 pm
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 14th, 2023 8:01 pm
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
- Jul 31st, 2023 12:00 pm
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
- Jul 27th, 2023 11:00 am
Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing
- Jun 28th, 2023 12:00 pm
Scroll